Casciato Manual de oncología clínica, Chmielowski, Bartosz

398  |  CAPÍTULO 16 • TUMORES ENDOCRINOS Jensen RT, Delle Fave G. Promising advances in the treatment of malignant pancreatic endocrine tumors. N Engl J Med 2011;364:564. Kulke MH. Clinical presentation and management of carcinoid tumors. Hematol Oncol Clin North Am 2007;21:433. Luis SA, Pellikka PA. Carcinoid heart disease: diagnosis and management. Best Pract Res Clin Endocrinol Metab 2016;30(1):149. Nakakura EK, Bergsland EK. Islet cell carcinoma: neuroendocrine tumors of the pancreas and periampullary region. Hematol Oncol Clin North Am 2007;21:457. Okabayashi T, Shima Y, Sumiyoshi T et al. Diagnosis and management of insulinoma. World J Gastroenterol 2013;19(6):829. Pavel M, Baudin E, Couvelard A, et al. ENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2012;95(2):157. Pinchot SN, Holen K, Sippel RS, et al. Carcinoid tumors. Oncologist 2008;13:1255. Poncet G, Faucheron J-L, Walter T. Recent trends in the treatment of well-differentiated endocrine carcinoma of the small bowel. World J Gastroenterol 2010;16:1696. Zhou C, Zhang J, Zheng Y, et al. Pancreatic neuroendocrine tumors: a comprehensive review. Int J Cancer 2012;131:1013. Cáncer tiroideo Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016;26(1):1. Patel KN, Shaha AR. Poorly differentiated thyroid cancer. Curr Opin Otolaryngol Head Neck Surg 2014;22(2):121. Sabet A, Kim M. Postoperative management of differentiated thyroid cancer. Otolaryngol Clin North Am 2010;43:329. Thomas L, Lai SY, Dong W, et al. Sorafenib in metastatic thyroid cancer: a systematic review. Oncologist 2014;19(3):251. Wells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 2015;25:567. Feocromocitoma Adjallé R, Plovin PF, Pacak K, et al. Treatment of malignant pheochromocytoma. Horm Metab Res 2009;41:687. Lenders JWM, Quan-Yang D, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014;99(6):1915. Mittendorf EA, Evans DB, Lee JE, et al. Pheochromocytoma: advances in genetics, diagnosis, localization and treatment. Hematol Oncol Clin North Am 2007;21:509. Pacak K. Perioperative management of the pheochromocytoma patient. J Clin Endocrinol Metab 2007;92:4069. Petri B-J, Van Eijck CHJ, de Herder WW, et al. Phaeochromocytomas and sympathetic paragangliomas. Br J Surg 2009;96:1381. Carcinoma de la corteza suprarrenal Baudin E. Adrenocortical carcinoma. Endocrinol Metab Clin North Am 2015;44:411. Fassnacht M, Allolio B. What is the best approach to an apparently nonmetastatic adrenocortical carcinoma? Clin Endocrinol (Oxf) 2010;73:561. Lacroix A. Approach to the patient with adrenocortical carcinoma. J Clin Endocrinol Metab 2010;95:4812. Veytsman I, Nieman L, Fojo T. Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma. J Clin Oncol 2009;27:4619. Young WF Jr. The incidentally discovered adrenal mass. N Engl J Med 2007;356:601. AMPLE